Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 12;18(10):e1003771.
doi: 10.1371/journal.pmed.1003771. eCollection 2021 Oct.

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors

Christopher Abbosh  1 , Charles Swanton  1   2
Affiliations

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors

Christopher Abbosh et al. PLoS Med. .

Abstract

Christopher Abbosh and Charles Swanton discuss circulating tumor DNA as a potential biomarker for neoadjuvant treatment response in solid tumors.

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: C.A. receives research salary from AstraZeneca and is an AstraZeneca Fellow and acting study physician on the MERMAID studies. C.A. and C.S. holds pending patents in methods to detect tumor recurrence (PCT/GB2017/053289) and declare patent PCT/US2017/028013 for methods to detect lung cancer. C.A. has received speaker fees from Novartis, Roche Diagnostics, Bristol Myers Squibb, and AstraZeneca and was an advisory board member for AstraZeneca. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Invitae (collaboration in minimal residual disease sequencing technologies), and Ono Pharmaceutical; is an AstraZeneca advisory board member and chief investigator for the MeRmaiD1 and 2 clinical trials; has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb, Celgene, Amgen, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, Metabomed and the Sarah Cannon Research Institute; has stock options in Apogen Biotechnologies, Epic Bioscience, and GRAIL; and has stock options and is co-founder of Achilles Therapeutics. C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), and identifying patients who respond to cancer treatment (PCT/GB2018/051912), as well as a US patent relating to detecting tumor mutations (PCT/US2017/28013) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892).

References

    1. Chauhan PS, Chen K, Babbra RK, Feng W, Pejovic N, Nallicheri A, et al.. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study. PloS Med. 2021. doi: 10.1371/journal.pmed.1003732 - DOI - PMC - PubMed
    1. Wang Y, Yang L, Bao H, Fan X, Xia F, Wan J, et al.. Utility of ctDNA in Predicting Response to Neoadjuvant Chemoradiotherapy and Prognosis Assessment in Locally Advanced Rectal Cancer: A Prospective Cohort Study. PloS Med. 2021. doi: 10.1371/journal.pmed.1003741 - DOI - PMC - PubMed
    1. Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, et al.. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PloS Med. 2021. doi: 10.1371/journal.pmed.1003620 - DOI - PMC - PubMed
    1. Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, et al.. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer. 2020;1(2):176–83. doi: 10.1038/s43018-019-0011-0 - DOI - PMC - PubMed
    1. Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, et al.. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clinical Cancer Research. 2018;24(24):6212–22. doi: 10.1158/1078-0432.CCR-18-0386 - DOI - PubMed

Publication types